Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibit GSK-3β or there’s heartbreak dead ahead
Elizabeth Murphy
Elizabeth Murphy
View: Text | PDF
Commentary

Inhibit GSK-3β or there’s heartbreak dead ahead

  • Text
  • PDF
Abstract

Numerous signaling pathways have been shown to mediate cardioprotection, but the end effectors that mediate protection are only beginning to be elucidated. Numerous cardioprotective drugs are shown to converge on glycogen synthase kinase-3β (GSK-3β) . The phosphorylation and inhibition of GSK-3β lead to inhibition or delayed activation of the mitochondrial permeability transition, a key regulator of apoptosis.

Authors

Elizabeth Murphy

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
GSK-3β is phosphorylated and inhibited by a number of kinases. In the ab...
GSK-3β is phosphorylated and inhibited by a number of kinases. In the absence of upstream kinases, unphosphorylated GSK-3β is active, and it phosphorylates and inactivates downstream targets such as glycogen synthase to modulate metabolism or phosphorylates transcription factors and targets them for degradation. Juhaszova et al. (9) suggest that phosphorylation and inactivation of GSK-3β also reduce activity of the MPT. Most GSK-3β substrates are phosphorylated by another kinase prior to phosphorylation by GSK-3β (12). GS, glycogen synthase; p70s6k, p70 ribosomal S6 kinase; RSK, p90 ribosomal S6 kinase; ILK, integrin-linked kinase; WNT, homologues of Wingless; P, phosphorylation.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts